KLF6 and glioblastoma: KLF6-SV1 lacks the anti-inflammatory function of the full-length protein and correlates with a more aggressive behavior and drug-resistance in GBM [91,93], suggesting that its impact on cytokine expression favors the establishment of a more malignant TME (Table 2).